Research · Sep 3, 2026
[CRL] Charles River Labs Thesis 2026: Biopharma R&D Cycle Tests Preclinical Services Recovery
Charles River Laboratories International, Inc. (NYSE: CRL) FY2025 revenue ~$4.0-4.2B (-5 to 0%) with adj. EPS ~$5.50-7.50 reflecting continued post-2024 biopharma R&D cycle trough stabilization (~$8B-$10B FY2024 trough biopharma VC + IPO funding vs ~$15B FY2022 peak) + selected DSA preclinical CRO market leadership (~30%+ share) + selected cell/gene therapy CDMO buildout via 2021 Vigene + Cognate BioServices acquisitions + selected continued long-term strategic continuity under CEO James Foster (~33-year tenure since 1992 — one of longest-tenured S&P 500 CEOs). Leading global research models + preclinical drug development services firm focused on enabling biopharma drug discovery + safety testing + biologics manufacturing. Founded 1947 by Henry Foster as Charles River Breeding Laboratories in Brookline Massachusetts (~78-year heritage; selected initial focus on selected research animal breeding); IPO 2000 NYSE; selected various transformative acquisitions through history including 2014 Argenta + BioFocus $135M (drug discovery) + 2018 MPI Research $800M (preclinical safety) + 2020 HemaCare $380M (cell therapy) + 2021 Vigene Biosciences $292M (gene therapy manufacturing) + 2021 Cognate BioServices $875M (cell + gene therapy manufacturing) + April 2024 Noveprim Group $400M (research models). Headquartered in Wilmington Massachusetts; ~21,000+ employees globally (~80+ facilities across ~25+ countries) with ~$4.0-4.2B revenue. Three reporting segments: Research Models & Services ~25% revenue ($1.0B — research animal models supply globally; mice + rats + selected primates; ~50%+ global research models market share), Discovery & Safety Assessment (DSA) ~50% ($2.0B — preclinical drug discovery services ~$700-800M + GLP toxicology safety testing ~$1.0-1.2B; ~30%+ global preclinical CRO market share + selected major biopharma + biotech customers including selected top 20 pharma + selected emerging biotech), Manufacturing Solutions ~25% ($1.0B — biologics manufacturing + cell/gene therapy CDMO post-2021 acquisitions). Biopharma R&D cycle trough: FY2022 peak revenue ~$3.98B post-pandemic biopharma surge (~$15B+ aggregate biopharma R&D spending); FY2023 ~$4.13B continued momentum; FY2024 trough ~$4.05B (-5% YoY post-pandemic biopharma R&D compression as biopharma firms tightened R&D budgets ~30-40% from peak; biotech IPO drought 2022-2024 reducing emerging biopharma client funding); selected post-2024 biopharma R&D stabilization reflected in continued large biopharma steady R&D + post-2024 IRA negotiation clarity + post-2024 obesity/GLP-1 + AI drug discovery driving new R&D commitment; FY2026 catalyst: biopharma R&D stabilization + new bookings recovery + backlog growth supporting revenue toward $4.2-4.5B (+5-7%). CEO James C. Foster since 1992 (~33-year tenure; founder Henry Foster's son; one of longest-tenured S&P 500 CEOs). Capital return: $0 dividend FY2025 (no dividend); $1-2B buyback program FY2025; investment-grade Baa2/BBB credit ratings; FCF $300-500M. FY2026 thesis: biopharma R&D stabilization + DSA backlog conversion + cell/gene therapy CDMO ramp + buyback continuation. Risks: major biopharma R&D cycle deterioration, DSA market share loss, cell/gene therapy CDMO competitive intensity, currency translation severe.